In November 2020, Myasthenia Gravis Foundation of America (MGFA) released International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update online. In addition to retaining seven topics for myasthenia gravis, two new topics (ocular myasthenia gravis and immune checkpoint inhibitor-associated myasthenia gravis) were included in this guideline. Furthermore, the previous recommendations for thymectomy were updated, and the new recommendations were developed for the use of rituximab, eculizumab, and methotrexate in the topic of myasthenia gravis and immunosuppression therapy. This paper summarizes the updated recommendations and new contents in this guideline.